APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

APEIRON Biologics 和 MaxCyte 签订 APN401临床和商业许可协议

2020-07-08 15:00:37 CISION

本文共1315个字,阅读需4分钟

 APEIRON Biologics AG , a private biotechnology company specializing in the discovery, development and commercialization of novel immunotherapies for cancer and respiratory diseases, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announces the signing of a clinical and commercial licensing agreement. APEIRON Biologics will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for the advancement of APN401, a siRNA-based cell therapy currently in clinical development for various solid tumors. In return, MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to other licensing fees. "Securing access to MaxCyte's ExPERT platform and unique electroporation technology is a crucial next step in the clinical advancement of our lead checkpoint inhibition Cbl-b candidate APN401," said Peter Llewellyn-Davies, CEO of APEIRON Biologics. Doug Doerfler, President & CEO of MaxCyte, said: "We are proud to support APEIRON in the development of a siRNA-based treatment that could help patients facing cancers with various forms of tumors. This agreement represents an important achievement for MaxCyte, and highlights the value of our next-generation technology platform to companies across the globe seeking to unlock the potential of their engineered cell therapy programs." MaxCyte's ExPERT instrument portfolio represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics. About APEIRON Biologics AG APEIRON Biologics AG is a European private biotechnology company based in Vienna that specializes in the discovery, development and commercialization of novel immunotherapies for cancer and respiratory diseases. APEIRON's approved cancer drug Qarziba® is being marketed by EUSA Pharma Ltd.. With APN01, APEIRON is conducting a clinical trial in Europe for the treatment of COVID-19, for which market approval is being sought. APEIRON's APN401 clinical program is a "first-in-class" autologous cell therapy for strengthening immunoreactivity via the intra-cellular master checkpoint Cbl-b. APEIRON's products and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions. For more information, visit www.apeiron-biologics.com. About MaxCyte MaxCyte, the clinical-stage global cell-based therapies and life sciences company, uses its proprietary next-generation cell and gene therapies to revolutionise medical treatments and ultimately save lives. The Company's premier cell engineering enabling technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted to more than 100 cell therapy programs, with more than 70 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com. SOURCE MaxCyte, Inc. Related Links http://www.maxcyte.com
APEIRON Biologics AG 是一家专注于发现、开发和商业化新型免疫疗法治疗癌症和呼吸系统疾病的私有生物技术公司,全球细胞疗法和生命科学公司 MaxCyte , Inc .今天宣布签署临床和商业许可协议。 APEIRON Biologics 将获得非专有的临床和商业权利,可使用 MaxCyte 的流式电子公司®技术和 ExPERT ™平台来推进 APN401的发展, APN401是一种基于 siRNA 的细胞疗法,目前正在针对各种实体肿瘤进行临床开发。作为回报,除其他许可费用外, MaxCyte 还将收到未披露的开发和批准里程碑以及基于销售的付款。 APEIRON Biologics 首席执行官 Peter Llewellin-Davies 说:“确保获得 MaxCyte 的 ExPERT 平台和独特的电穿孔技术是我们领先检查点抑制 Cbl-b 候选 APN401临床进展的关键下一步。” MaxCyte 公司总裁兼首席执行官 DougDoerler 说:“我们很自豪能够支持 APEIRON 开发一种基于 siRNA 的治疗方法,帮助面临各种肿瘤的癌症患者。这项协议是 MaxCyte 的一项重要成就,也突出了我们下一代技术平台对全球公司的价值,这些公司寻求释放其工程细胞治疗项目的潜力。” MaxCyte 公司的 ExPERT 仪器组合代表了下一代领先的、临床验证的、用于复杂和可扩展细胞工程的电穿孔技术。ExPERT 平台通过提供高效的转染效率、无缝的可扩展性和增强的功能,提供了实现下一波生物和细胞治疗所必需的高端性能。 关于 APEIRON 生物技术公司 APEIRON Biologics AG 是一家位于维也纳的欧洲私有生物技术公司,专门从事癌症和呼吸系统疾病的新型免疫疗法的发现、开发和商业化。APEIRON 批准的抗癌药物 Qarziba ®正在由 EUSA Pharma Ltd .上市。APN01正在欧洲进行治疗 COVID-19的临床试验,目前正在寻求市场批准。APEIRON 的 APN401临床方案是一种“一流”的自体细胞疗法,通过细胞内的主检查点 Cbl-b 增强免疫反应性。APEIRON 的产品和技术基于强大的专利组合和与领先制药公司和学术机构的合作伙伴关系。有关更多信息,请访问 www.apartin-biologics 。com 。 关于 MaxCyte 临床阶段的全球细胞疗法和生命科学公司 MaxCyte 使用其专有的下一代细胞和基因疗法来彻底改变医疗治疗并最终挽救生命。本公司的首要细胞工程授权技术目前正由全球领先的药物开发商部署,包括全球十大生物制药公司。MaxCyte 许可已被授予100多个细胞治疗方案,其中70多个获得临床使用许可,本公司现已与领先的细胞治疗和基因编辑开发商达成11个临床/商业许可合作伙伴关系。MaxCyte 成立于1998年,总部位于美国马里兰州 Gaithersburg 。有关详细信息,请访问 www.maxcell.com 。 SoURCE MaxCyte , Inc . 相关链接 http://www.maxcell.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文